TIP or BEP for Intermediate or Poor Risk Testicular Cancer?: Highlights in GU Oncology from ASCO 2018 (BMIC-061)
Aug 31, 2018•4 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Dr. Dan Goldstein reviews results of a trial of chemo regimen TIP (paclitaxel, ifosfamide, cisplatin) vs BEP (bleomycin, etoposide, cisplatin) for intermediate/poor risk germ cell tumors, with discussion of outcomes in patients with a p53 mutation.
For the best experience, listen in Metacast app for iOS or Android
Open in Metacast